negative control nc sirna Search Results


90
Ribobio co sirnas targeting lnc rna dancr and non-specific control (nc)
Sirnas Targeting Lnc Rna Dancr And Non Specific Control (Nc), supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pmc05122356-128-7-13?v=Ribobio+co
Average 90 stars, based on 1 article reviews
sirnas targeting lnc rna dancr and non-specific control (nc) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
BONAC Corporation negative control sirna
Negative Control Sirna, supplied by BONAC Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pm23221504-44-11-18?v=BONAC+Corporation
Average 90 stars, based on 1 article reviews
negative control sirna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Ribobio co negative control sirna (sinc)
Negative Control Sirna (Sinc), supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/10__7554_slash_elife__42426-395-6-19?v=Ribobio+co
Average 90 stars, based on 1 article reviews
negative control sirna (sinc) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Ribobio co control sirna si-nc
Control Sirna Si Nc, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pmc11853609-59-7-13?v=Ribobio+co
Average 90 stars, based on 1 article reviews
control sirna si-nc - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Ribobio co pfn1 sirna
<t>PFN1</t> is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.
Pfn1 Sirna, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pmc09108340-61-0-10?v=Ribobio+co
Average 90 stars, based on 1 article reviews
pfn1 sirna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
siTools Biotech negative control sirna pool
<t>PFN1</t> is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.
Negative Control Sirna Pool, supplied by siTools Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pmc07826283-61-14-18?v=siTools+Biotech
Average 90 stars, based on 1 article reviews
negative control sirna pool - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma sirnas targeting hottip, hoxa13, wdr5, mll1, mll2, mll3, cyp26b1, cyb5r2, ucp2, sult1a1, clic5, and chi3l1
<t>PFN1</t> is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.
Sirnas Targeting Hottip, Hoxa13, Wdr5, Mll1, Mll2, Mll3, Cyp26b1, Cyb5r2, Ucp2, Sult1a1, Clic5, And Chi3l1, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pm32120024-58-15-25?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
sirnas targeting hottip, hoxa13, wdr5, mll1, mll2, mll3, cyp26b1, cyb5r2, ucp2, sult1a1, clic5, and chi3l1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Microsynth ag negative control sirna
(A) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in HEK 293 Phoenix <t>cells</t> <t>transfected</t> for 48 hours with LIPT2 or a transfection marker (control). (B) Levels of the transcript of LIPT2 detected by RT-PCR in HEK 293 Phoenix cells transfected for 48 hours with <t>siRNA</t> #1, 2 and 3 or control siRNA (control) and normalized for the levels of the transcript of the housekeeping gene β-ACTIN . Gene silencing of 7, 48 and 25% was obtained, respectively. (C) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in cells transfected with siRNA #2 or a control siRNA (control). n.s., not significant, **, ***: p<0.01, p<0.001, unpaired Student’s t test. (n) in A and C indicates the number of cells. In B, n = 3 for each condition.
Negative Control Sirna, supplied by Microsynth ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pmc05476274-116-8-10?v=Microsynth+ag
Average 90 stars, based on 1 article reviews
negative control sirna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma negative control sirna
(A) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in HEK 293 Phoenix <t>cells</t> <t>transfected</t> for 48 hours with LIPT2 or a transfection marker (control). (B) Levels of the transcript of LIPT2 detected by RT-PCR in HEK 293 Phoenix cells transfected for 48 hours with <t>siRNA</t> #1, 2 and 3 or control siRNA (control) and normalized for the levels of the transcript of the housekeeping gene β-ACTIN . Gene silencing of 7, 48 and 25% was obtained, respectively. (C) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in cells transfected with siRNA #2 or a control siRNA (control). n.s., not significant, **, ***: p<0.01, p<0.001, unpaired Student’s t test. (n) in A and C indicates the number of cells. In B, n = 3 for each condition.
Negative Control Sirna, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pm27980455-74-3-9?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
negative control sirna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma 6-carboxyfluorescein-tagged, negative control (nc) scrambled sirnas
(A) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in HEK 293 Phoenix <t>cells</t> <t>transfected</t> for 48 hours with LIPT2 or a transfection marker (control). (B) Levels of the transcript of LIPT2 detected by RT-PCR in HEK 293 Phoenix cells transfected for 48 hours with <t>siRNA</t> #1, 2 and 3 or control siRNA (control) and normalized for the levels of the transcript of the housekeeping gene β-ACTIN . Gene silencing of 7, 48 and 25% was obtained, respectively. (C) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in cells transfected with siRNA #2 or a control siRNA (control). n.s., not significant, **, ***: p<0.01, p<0.001, unpaired Student’s t test. (n) in A and C indicates the number of cells. In B, n = 3 for each condition.
6 Carboxyfluorescein Tagged, Negative Control (Nc) Scrambled Sirnas, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pm28693266-37-6-22?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
6-carboxyfluorescein-tagged, negative control (nc) scrambled sirnas - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Ribobio co silencer negative control sirnas
Silencing <t>CAV2,</t> <t>PHLDA1,</t> and VDAC3 separately significantly increases sensitivity to cisplatin. A – C qRT-PCR and Western blot showing CAV2, PHLDA1, and VDAC3 knockdown 48 and 72 h after transfection with CAV2-targeting, PHLDA1-targeting and VDAC3-targeting <t>siRNAs.</t> D : cytotoxicity curves of the LUAD cell lines A549, PC9 and ESCC cell line TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with different concentrations of cisplatin (0, 2.5, 5, 10, 20, 40 μM). E EdU for A549, PC9 and TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with cisplatin (10 μM)
Silencer Negative Control Sirnas, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pmc10249226-56-6-13?v=Ribobio+co
Average 90 stars, based on 1 article reviews
silencer negative control sirnas - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma control sirna nc (si)
Silencing <t>CAV2,</t> <t>PHLDA1,</t> and VDAC3 separately significantly increases sensitivity to cisplatin. A – C qRT-PCR and Western blot showing CAV2, PHLDA1, and VDAC3 knockdown 48 and 72 h after transfection with CAV2-targeting, PHLDA1-targeting and VDAC3-targeting <t>siRNAs.</t> D : cytotoxicity curves of the LUAD cell lines A549, PC9 and ESCC cell line TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with different concentrations of cisplatin (0, 2.5, 5, 10, 20, 40 μM). E EdU for A549, PC9 and TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with cisplatin (10 μM)
Control Sirna Nc (Si), supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+control+nc+sirna/pmc11861500-154-41-49?v=Shanghai+GenePharma
Average 90 stars, based on 1 article reviews
control sirna nc (si) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


PFN1 is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: PFN1 is correlated with NSCLC metastasis and could promote NSCLC cell migration in vitro . (A) Representative IHC images of PFN1 expression on the NSCLC tissues. (B) The staining index of PFN1 on the tissue chip. ** p < 0.01. (C) Representative IHC images of PFN1 expression on the tissue chip. (D) The expression of PFN1 in TCGA LUAD data. ** p < 0.01. (E) The Kaplan–Meier survival analysis of PFN1 in NSCLC patients. (Data source: TCGA LUAD dataset) (F,G) Wound healing assays conducted to evaluate the migration ability of PFN1 -overexpressing (F) and PFN1 knockdown (KD) (G) H1299 cells. ** p < 0.01; scale bar, 500 μm. (H,I) Transwell migration assays conducted to evaluate the migration of PFN1 -overexpressing (H) and PFN1 KD (I) H1299 cells. ** p < 0.01; scale bar, 500 μm. EV, empty vector; OE, PFN1 overexpression; NC, negative control; si-1/ 2, PFN1 siRNA1 1/2.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Migration, In Vitro, Expressing, Staining, Knockdown, Plasmid Preparation, Over Expression, Negative Control

PFN1 could promote MVs secretion in NSCLC. (A) Heatmap of differentially expressed proteins between EV and PFN1 OE cells. (B) GO enrichment analysis of differentially expressed proteins. (C) COG/KOG analysis of differentially expressed proteins. (D) MVs extracted from EV-expressing and PFN1 -overexpressing cells, using continuous differential centrifugation, identified using transmission electron microscopy. Scale bar, 100 nm. (E,F) Flow cytometry (E) and western blotting (F) were used to quantify MVs in PFN1 -overexpressing and EV-expressing cells. ARF6 and actin were used as MV markers. (G) Expression of PFN1 and annexin A1 in lung tumor tissues detected using immunofluorescence. (H) The staining index of p-MLC on the tissue chip. ** p < 0.01. (I) Representative IHC images of p-MLC expression. (J) Spearman rank correlation analysis was used to assess the relationship between PFN1 and p-MLC expression on the tissue chip; p and r values are shown in the plot.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: PFN1 could promote MVs secretion in NSCLC. (A) Heatmap of differentially expressed proteins between EV and PFN1 OE cells. (B) GO enrichment analysis of differentially expressed proteins. (C) COG/KOG analysis of differentially expressed proteins. (D) MVs extracted from EV-expressing and PFN1 -overexpressing cells, using continuous differential centrifugation, identified using transmission electron microscopy. Scale bar, 100 nm. (E,F) Flow cytometry (E) and western blotting (F) were used to quantify MVs in PFN1 -overexpressing and EV-expressing cells. ARF6 and actin were used as MV markers. (G) Expression of PFN1 and annexin A1 in lung tumor tissues detected using immunofluorescence. (H) The staining index of p-MLC on the tissue chip. ** p < 0.01. (I) Representative IHC images of p-MLC expression. (J) Spearman rank correlation analysis was used to assess the relationship between PFN1 and p-MLC expression on the tissue chip; p and r values are shown in the plot.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Expressing, Centrifugation, Transmission Assay, Electron Microscopy, Flow Cytometry, Western Blot, Immunofluorescence, Staining

MVs derived from PFN1 OE cells promote migration in NSCLC cells. (A) MVs collected from sera of patients with NSCLC quantified using flow cytometry. ** p < 0.01. (B) Protein expression of ARF6 and β-actin in MVs collected from sera of patients with NSCLC detected using western blotting. (C) Effect of PFN1 -overexpressing cell supernatants on cell migration evaluated through wound healing assays. ** p < 0.01; scale bar, 500 μm. (D) PKH67-labeled MVs taken up by H1299 cells. DAPI was used to stain the nuclei of H1299 cells. Scale bar, 500 μm. (E,F) Wound healing (E) and Transwell migration (F) assays conducted to evaluate the migration of H1299 cells after treatment with MVs derived from EV-expressing and PFN1 -overexpressing cells; ** p < 0.01; scale bar, 500 μm.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: MVs derived from PFN1 OE cells promote migration in NSCLC cells. (A) MVs collected from sera of patients with NSCLC quantified using flow cytometry. ** p < 0.01. (B) Protein expression of ARF6 and β-actin in MVs collected from sera of patients with NSCLC detected using western blotting. (C) Effect of PFN1 -overexpressing cell supernatants on cell migration evaluated through wound healing assays. ** p < 0.01; scale bar, 500 μm. (D) PKH67-labeled MVs taken up by H1299 cells. DAPI was used to stain the nuclei of H1299 cells. Scale bar, 500 μm. (E,F) Wound healing (E) and Transwell migration (F) assays conducted to evaluate the migration of H1299 cells after treatment with MVs derived from EV-expressing and PFN1 -overexpressing cells; ** p < 0.01; scale bar, 500 μm.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Derivative Assay, Migration, Flow Cytometry, Expressing, Western Blot, Labeling, Staining

PFN1 promotes in vivo NSCLC metastasis by elevating MV secretion. (A) Schematic illustration of the mouse model of metastatic tumor established to determine the role of PFN1 in tumor metastasis. (B) Body weight changes in mice after intracardiac injection of PFN1 -overexpressing and EV-expressing cell lines. (C,D) Representative images of lung (C) and liver (D) metastases of the mouse model. The number of metastases is displayed in the right-hand side graph. * p < 0.05, ** p < 0.01. (E) Representative images of HE-stained lung tissues of the mouse model. (F) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (G) Representative images of HE-stained liver tissues of the mouse model. (H) Representative IHC images of PFN1 and p-MLC expression in liver tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (I) Body weight changes in mice after intracardiac injection of H1299 cells and MVs. (J) Representative images of lung metastases of the mouse model. The number of metastases is shown in the bottom graph. * p < 0.05. (K) Representative images of HE-stained lung tissues of the mouse model. (L) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph; * p < 0.05.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: PFN1 promotes in vivo NSCLC metastasis by elevating MV secretion. (A) Schematic illustration of the mouse model of metastatic tumor established to determine the role of PFN1 in tumor metastasis. (B) Body weight changes in mice after intracardiac injection of PFN1 -overexpressing and EV-expressing cell lines. (C,D) Representative images of lung (C) and liver (D) metastases of the mouse model. The number of metastases is displayed in the right-hand side graph. * p < 0.05, ** p < 0.01. (E) Representative images of HE-stained lung tissues of the mouse model. (F) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (G) Representative images of HE-stained liver tissues of the mouse model. (H) Representative IHC images of PFN1 and p-MLC expression in liver tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (I) Body weight changes in mice after intracardiac injection of H1299 cells and MVs. (J) Representative images of lung metastases of the mouse model. The number of metastases is shown in the bottom graph. * p < 0.05. (K) Representative images of HE-stained lung tissues of the mouse model. (L) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph; * p < 0.05.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: In Vivo, Injection, Expressing, Staining

Mechanisms underlying the promotion of MLC phosphorylation by PFN1. (A,B) Protein expression after PFN1 overexpression (A) and knockdown (B) measured using western blotting. (C) Protein expression in PFN1 mutants measured using western blotting. (D) PFN1 interactions with ROCK1/2 confirmed using co-IP. (E) Protein expression after treatment with Y27632 (10 µM) measured using western blotting. (F) Effect of PFN1 on ROCK1 activity. ** p < 0.01. (G) Effect of PFN1 on ROCK2 activity. (H) Flow cytometry measuring changes in the amount of MVs after treatment with Y27632; * p < 0.05.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: Mechanisms underlying the promotion of MLC phosphorylation by PFN1. (A,B) Protein expression after PFN1 overexpression (A) and knockdown (B) measured using western blotting. (C) Protein expression in PFN1 mutants measured using western blotting. (D) PFN1 interactions with ROCK1/2 confirmed using co-IP. (E) Protein expression after treatment with Y27632 (10 µM) measured using western blotting. (F) Effect of PFN1 on ROCK1 activity. ** p < 0.01. (G) Effect of PFN1 on ROCK2 activity. (H) Flow cytometry measuring changes in the amount of MVs after treatment with Y27632; * p < 0.05.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Phospho-proteomics, Expressing, Over Expression, Knockdown, Western Blot, Co-Immunoprecipitation Assay, Activity Assay, Flow Cytometry

ROCK1 inhibitor Y27632 partially reversed the promotion of lung cancer metastasis by PFN1 in vitro and in vivo . (A,B) Wound healing assays conducted to evaluate the effect of Y27632 (A) and Y27632 combined with MVs (B) on cell migration. ** p < 0.01; scale bar, 500 μm. (C) Transwell migration assays conducted to evaluate the effect of Y27632 and Y27632 combined with MVs on cell migration. ** p < 0.01; scale bar, 500 μm. (D) Schematic diagram of the mouse model of metastatic tumor established to determine the effect of Y27632 on PFN1-induced lung cancer metastasis. (E) Body weight changes in mice after intracardiac injection of PFN1 -overexpressing H1299 cells and intraperitoneal injection of Y27632 (10 mg/kg). (F) Representative images of lung and liver metastatic tissue in mice. The number of metastatic nodules is shown in the right-hand side graph. * p < 0.05. (G,H) Representative images of HE-stained lung (G) and liver (H) metastases. (I) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (J) Representative IHC images of PFN1 and p-MLC expression in liver tissues. The staining index is shown in the right-hand side graph; ** p < 0.01.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: ROCK1 inhibitor Y27632 partially reversed the promotion of lung cancer metastasis by PFN1 in vitro and in vivo . (A,B) Wound healing assays conducted to evaluate the effect of Y27632 (A) and Y27632 combined with MVs (B) on cell migration. ** p < 0.01; scale bar, 500 μm. (C) Transwell migration assays conducted to evaluate the effect of Y27632 and Y27632 combined with MVs on cell migration. ** p < 0.01; scale bar, 500 μm. (D) Schematic diagram of the mouse model of metastatic tumor established to determine the effect of Y27632 on PFN1-induced lung cancer metastasis. (E) Body weight changes in mice after intracardiac injection of PFN1 -overexpressing H1299 cells and intraperitoneal injection of Y27632 (10 mg/kg). (F) Representative images of lung and liver metastatic tissue in mice. The number of metastatic nodules is shown in the right-hand side graph. * p < 0.05. (G,H) Representative images of HE-stained lung (G) and liver (H) metastases. (I) Representative IHC images of PFN1 and p-MLC expression in lung tissues. The staining index is shown in the right-hand side graph. ** p < 0.01. (J) Representative IHC images of PFN1 and p-MLC expression in liver tissues. The staining index is shown in the right-hand side graph; ** p < 0.01.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: In Vitro, In Vivo, Migration, Injection, Staining, Expressing

Schematic diagram of the role of PFN1 in NSCLC metastasis. In the initiation stage of NSCLC, cells with upregulated PFN1 secret more MVs through PFN1 interactions with the ROCK/p-MLC pathway. These MVs contain numerous oncogenenic moleculars, which could enhance migration abilities of PFN1 normal expressed NSCLC cells, and untimately promote progression and metastasis of NSCLC.

Journal: Frontiers in Pharmacology

Article Title: Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer

doi: 10.3389/fphar.2022.890891

Figure Lengend Snippet: Schematic diagram of the role of PFN1 in NSCLC metastasis. In the initiation stage of NSCLC, cells with upregulated PFN1 secret more MVs through PFN1 interactions with the ROCK/p-MLC pathway. These MVs contain numerous oncogenenic moleculars, which could enhance migration abilities of PFN1 normal expressed NSCLC cells, and untimately promote progression and metastasis of NSCLC.

Article Snippet: PFN1 siRNA and control scramble siRNA were synthesized by Guangzhou RiboBio Co. (Guangzhou, China), and the sequences are listed in .

Techniques: Migration

(A) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in HEK 293 Phoenix cells transfected for 48 hours with LIPT2 or a transfection marker (control). (B) Levels of the transcript of LIPT2 detected by RT-PCR in HEK 293 Phoenix cells transfected for 48 hours with siRNA #1, 2 and 3 or control siRNA (control) and normalized for the levels of the transcript of the housekeeping gene β-ACTIN . Gene silencing of 7, 48 and 25% was obtained, respectively. (C) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in cells transfected with siRNA #2 or a control siRNA (control). n.s., not significant, **, ***: p<0.01, p<0.001, unpaired Student’s t test. (n) in A and C indicates the number of cells. In B, n = 3 for each condition.

Journal: PLoS ONE

Article Title: Mis-targeting of the mitochondrial protein LIPT2 leads to apoptotic cell death

doi: 10.1371/journal.pone.0179591

Figure Lengend Snippet: (A) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in HEK 293 Phoenix cells transfected for 48 hours with LIPT2 or a transfection marker (control). (B) Levels of the transcript of LIPT2 detected by RT-PCR in HEK 293 Phoenix cells transfected for 48 hours with siRNA #1, 2 and 3 or control siRNA (control) and normalized for the levels of the transcript of the housekeeping gene β-ACTIN . Gene silencing of 7, 48 and 25% was obtained, respectively. (C) Current density (pA/pF) to voltage (mV) relationship measured in hypertonic solution and after a 10 minutes exposure to a hypotonic solution (left) and current density (pA/pF) to time (sec) relationship measured in hypotonic solution (right) in cells transfected with siRNA #2 or a control siRNA (control). n.s., not significant, **, ***: p<0.01, p<0.001, unpaired Student’s t test. (n) in A and C indicates the number of cells. In B, n = 3 for each condition.

Article Snippet: Control cells were transfected with the following negative control siRNA (Microsynth CH): 5’-GCA GCA CGA CUU CUU CAA GTT-3’ .

Techniques: Transfection, Marker, Control, Reverse Transcription Polymerase Chain Reaction

Silencing CAV2, PHLDA1, and VDAC3 separately significantly increases sensitivity to cisplatin. A – C qRT-PCR and Western blot showing CAV2, PHLDA1, and VDAC3 knockdown 48 and 72 h after transfection with CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs. D : cytotoxicity curves of the LUAD cell lines A549, PC9 and ESCC cell line TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with different concentrations of cisplatin (0, 2.5, 5, 10, 20, 40 μM). E EdU for A549, PC9 and TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with cisplatin (10 μM)

Journal: Cell & Bioscience

Article Title: The genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data

doi: 10.1186/s13578-023-01061-z

Figure Lengend Snippet: Silencing CAV2, PHLDA1, and VDAC3 separately significantly increases sensitivity to cisplatin. A – C qRT-PCR and Western blot showing CAV2, PHLDA1, and VDAC3 knockdown 48 and 72 h after transfection with CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs. D : cytotoxicity curves of the LUAD cell lines A549, PC9 and ESCC cell line TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with different concentrations of cisplatin (0, 2.5, 5, 10, 20, 40 μM). E EdU for A549, PC9 and TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with cisplatin (10 μM)

Article Snippet: siRNAs targeting PHLDA1, CAV2, VDAC3, and Silencer Negative Control siRNAs were purchased from Ribobio (sequences provided in Additional file : Table S1).

Techniques: Quantitative RT-PCR, Western Blot, Knockdown, Transfection